#141 Management of Menopausal Symptoms Flashcards
What are the prevalence of vasomotor symptoms among women experiencing natural menopause?
50-82%
When does occurence of vasomotor symptoms peak during menopausal transition?
Approximately 1 year after the final menstrual period
What is the median age of menopause in North America?
51yo
What are other terms for “perimenopause”
The climacteric or the menopausal transition
What happens to estrogen levels during menopausal transition?
Decreases
What happens to progesterone levels during menopausal transition?
Decreases
What happens to FSH levels during menopausal transition?
Increases
How long does a vasomotor episode typically last?
1-5 minutes
Where on their bodies do women typically experience vasomotor symptoms?
Upper body, particularly face, neck, and chest
In women who experience hot flushes during menopausal transition, what percentage experience them daily?
87%
In women who experience hot flushes during menopausal transition, what percentage experience more than 10 per day?
33%
What is the median duration of time that women experience hot flushes?
Median duration of 4 years and 10.2 years have been reported
Does evidence show that the thermoregulatory zone of women is narrowed, widened, or stays the same during menopausal transition?
Narrows, one of the theories to explain hot flushes
Are hot flushes more or less common or no effect in obese women?
More common
What percentage of menopausal women experience 1 or more symptom of vaginal atrophy?
10-40%
What symptoms are associated with vaginal atrophy?
Vaginal or vulvar dryness, discharge, itching, dyspareunia, bleeding
What are physical signs of vaginal atrophy?
Thinning of tissue, loss of vaginal rugae and elasticity, narrowing/shortening of vagina, bleeding/fissures, loss of subcutaneous fat in labia majora, narrowing introitus, fusion of labia minora, shrinking of clitoral prepuce and urethra. More alkaline pH.
How does vaginal atrophy change risk of infections?
Increases risk of urogenital infection
What hormonal therapy is approved for treatment of vasomotor symptoms?
Estrogen alone or in combination with progestin. Data do not support progestin-only, testosterone, or compounded bioidentical hormones
What is the dose range for conjugated estrogen for hormone therapy?
0.3-0.625mg/d
What is the dose range for micronized estradiol-17beta for hormone therapy?
0.25-1mg/d
What is the dose range for transdermal estradiol-17beta for hormone therapy?
0.014-0.05mg/d
What dose of paroxetine is used for treatment of vasomotor symptoms?
7.5mg/d
What dose of clonidine is used for treatment of vasomotor symptoms?
0.1mg/d